109 related articles for article (PubMed ID: 8846537)
1. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
Steffensen G; Aunsholt NA; Povlsen JV
Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
[TBL] [Abstract][Full Text] [Related]
2. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin].
Tanabe R
Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin.
Bárány P; Fehrman I; Godoy C
Clin Nephrol; 1992 Feb; 37(2):90-6. PubMed ID: 1551255
[TBL] [Abstract][Full Text] [Related]
4. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
5. The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients.
Singh AB; Singh M; Palekar S; Levy S; Nunn C; Mann RA
J Med; 1992; 23(5):289-302. PubMed ID: 1469332
[TBL] [Abstract][Full Text] [Related]
6. Treatment of anaemia in CAPD patients with recombinant human erythropoietin.
Ramello A; Malcangi U; Bruno M; Perosa P; Reina E; Rizzuto A; Nasini MG; Carozzi S
Adv Perit Dial; 1990; 6():308-11. PubMed ID: 1982834
[TBL] [Abstract][Full Text] [Related]
7. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
8. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment.
Lisowska KA; Debska-Slizień A; Bryl E; Rutkowski B; Witkowski JM
Artif Organs; 2010 Aug; 34(8):654-62. PubMed ID: 20528849
[TBL] [Abstract][Full Text] [Related]
10. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin.
Schaefer RM; Kokot F; Wernze H; Geiger H; Heidland A
Clin Nephrol; 1989 Jan; 31(1):1-5. PubMed ID: 2914405
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of recombinant human erythropoietin in chronic renal failure.
van Dullemen HM; Luykx-de Bakker S; Hillen PH; van Landeghem AA; van Boven WP; van der Heul C
Neth J Med; 1992 Aug; 41(1-2):56-63. PubMed ID: 1407241
[TBL] [Abstract][Full Text] [Related]
12. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
Roger SD; Baker LR; Raine AE
Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of peripheral blood T lymphocytes and natural killer cells in alcoholic hepatitis persist after a 3-month withdrawal period.
Laso FJ; Madruga JI; López A; Ciudad J; Alvarez-Mon M; San Miguel J; Orfao A
Alcohol Clin Exp Res; 1997 Jun; 21(4):672-6. PubMed ID: 9194923
[TBL] [Abstract][Full Text] [Related]
14. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
15. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
Verbeelen D; Hauglustaine D; Sennesael J
Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
[No Abstract] [Full Text] [Related]
16. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
17. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Collins AJ
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
Hussein MM; Mooij JM; Roujouleh H
Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
[No Abstract] [Full Text] [Related]
19. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
